iBio Inc [IBIO] stock prices are up 5.79% to $1.28 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IBIO shares have gain 43.34% over the last week, with a monthly amount glided 57.83%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
iBio Inc [NASDAQ: IBIO] stock has seen the most recent analyst activity on October 21, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $5. Previously, Leerink Partners started tracking the stock with Outperform rating on October 17, 2025, and set its price target to $2. On May 28, 2024, Chardan Capital Markets initiated with a Buy rating and assigned a price target of $5 on the stock. JMP Securities started tracking the stock assigning a Mkt Outperform rating and suggested a price target of $1.50 on November 29, 2021. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $3 as its price target on January 22, 2021. Alliance Global Partners started tracking with a Buy rating for this stock on June 26, 2020, and assigned it a price target of $2.55.
The stock price of iBio Inc [IBIO] has been fluctuating between $0.56 and $6.89 over the past year. Currently, Wall Street analysts expect the stock to reach $2 within the next 12 months. iBio Inc [NASDAQ: IBIO] shares were valued at $1.28 at the most recent close of the market. An investor can expect a potential return of 56.25% based on the average IBIO price forecast.
Analyzing the IBIO fundamentals
The iBio Inc [NASDAQ:IBIO] reported sales of 0.40M for trailing twelve months, representing a surge of 14.29%. Gross Profit Margin for this corporation currently stands at 2.98% with Operating Profit Margin at -44.83%, Pretax Profit Margin comes in at -43.89%, and Net Profit Margin reading is -55.98%. To continue investigating profitability, this company’s Return on Assets is posted at -1.1, Equity is -1.3 and Total Capital is -1.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.26.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.1733 points at the first support level, and at 1.0667 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3533, and for the 2nd resistance point, it is at 1.4267.
Ratios To Look Out For
It’s worth pointing out that iBio Inc [NASDAQ:IBIO]’s Current Ratio is 1.59. Further, the Quick Ratio stands at 1.59, while the Cash Ratio is 0.92. Considering the valuation of this stock, the price to sales ratio is 64.82, the price to book ratio is 1.66.
Transactions by insiders
Recent insider trading involved Duran Felipe, Chief Financial Officer, that happened on Jan 10 ’25 when 9191.0 shares were purchased. See Remarks, Brenner Martin completed a deal on Jan 10 ’25 to buy 9191.0 shares. Meanwhile, Chief Legal Officer Banjak Marc bought 9191.0 shares on Jan 10 ’25.
